- A. Fasslet al., Increased lysosomal biomass is responsible for
the resistance of triple-negative breast cancers to CDK4/6
inhibition.Sci. Adv. 6 , eabb2210 (2020). doi:10.1126/sciadv.
abb2210; pmid: 32704543 - H. Wanget al., The metabolic function of cyclin D3-CDK6
kinase in cancer cell survival.Nature 546 , 426–430 (2017).
doi:10.1038/nature22797; pmid: 28607489 - C. Luoet al., Obesity/Type 2 Diabetes-Associated Liver
Tumors Are Sensitive to Cyclin D1 Deficiency.Cancer Res. 80 ,
3215 – 3221 (2020). doi:10.1158/0008-5472.CAN-20-0106;
pmid: 32606000 - S. Goelet al., CDK4/6 inhibition triggers anti-tumour
immunity.Nature 548 , 471–475 (2017). doi:10.1038/
nature23465; pmid: 28813415 - J. Denget al., CDK4/6 Inhibition Augments Antitumor
Immunity by Enhancing T-cell Activation.Cancer Discov. 8 ,
216 – 233 (2018). doi:10.1158/2159-8290.CD-17-0915;
pmid: 29101163 - D. A. Schaeret al., The CDK4/6 Inhibitor Abemaciclib
Induces a T Cell Inflamed Tumor Microenvironment and
Enhances the Efficacy of PD-L1 Checkpoint Blockade.
Cell Rep. 22 , 2978–2994 (2018). doi:10.1016/j.
celrep.2018.02.053; pmid: 29539425 - J. Yuet al., Genetic Aberrations in the CDK4 Pathway Are
Associated with Innate Resistance to PD-1 Blockade in
Chinese Patients with Non-Cutaneous Melanoma.
Clin. Cancer Res. 25 , 6511–6523 (2019). doi:10.1158/
1078-0432.CCR-19-0475; pmid: 31375512 - J. Zhanget al., Cyclin D-CDK4 kinase destabilizes PD-L1
via cullin 3-SPOP to control cancer immune surveillance.
Nature 553 , 91–95 (2018). doi:10.1038/nature25015;
pmid: 29160310 - X. Jinet al., Phosphorylated RB Promotes Cancer Immunity
by Inhibiting NF-kB Activation and PD-L1 Expression.
Mol. Cell 73 , 22–35.e6 (2019). doi:10.1016/
j.molcel.2018.10.034; pmid: 30527665 - L. Jerby-Arnonet al., A Cancer Cell Program Promotes T Cell
Exclusion and Resistance to Checkpoint Blockade.Cell 175 ,
984 – 997.e24 (2018). doi:10.1016/j.cell.2018.09.006;
pmid: 30388455 - Z. L. Teoet al., Combined CDK4/6 and PI3KaInhibition Is
Synergistic and Immunogenic in Triple-Negative Breast
Cancer.Cancer Res. 77 , 6340–6352 (2017). doi:10.1158/
0008-5472.CAN-17-2210; pmid: 28947417 - R. S. Finnet al., Palbociclib and Letrozole in Advanced Breast
Cancer.N. Engl. J. Med. 375 , 1925–1936 (2016).
doi:10.1056/NEJMoa1607303; pmid: 27959613 - N. C. Turneret al., Palbociclib in Hormone-Receptor-Positive
Advanced Breast Cancer.N. Engl. J. Med. 373 , 209– 219
(2015). doi:10.1056/NEJMoa1505270; pmid: 26030518 - M. Cristofanilliet al., Fulvestrant plus palbociclib versus
fulvestrant plus placebo for treatment of hormone-receptor-
positive, HER2-negative metastatic breast cancer that
progressed on previous endocrine therapy (PALOMA-3):
Final analysis of the multicentre, double-blind, phase 3
randomised controlled trial.Lancet Oncol. 17 , 425– 439
(2016). doi:10.1016/S1470-2045(15)00613-0;
pmid: 26947331 - G. N. Hortobagyiet al., Ribociclib as First-Line Therapy for
HR-Positive, Advanced Breast Cancer.N. Engl. J. Med.
375 , 1738–1748 (2016). doi:10.1056/NEJMoa1609709;
pmid: 27717303 - D. J. Slamonet al., Phase III Randomized Study of Ribociclib
and Fulvestrant in Hormone Receptor-Positive, Human
Epidermal Growth Factor Receptor 2-Negative Advanced
Breast Cancer: MONALEESA-3.J. Clin. Oncol. 36 , 2465– 2472
(2018). doi:10.1200/JCO.2018.78.9909; pmid: 29860922 - D. Tripathyet al., Ribociclib plus endocrine therapy for
premenopausal women with hormone-receptor-positive,
advanced breast cancer (MONALEESA-7): A randomised
phase 3 trial.Lancet Oncol. 19 , 904–915 (2018). doi:10.1016/
S1470-2045(18)30292-4; pmid: 29804902 - G. W. Sledge Jret al., MONARCH 2: Abemaciclib in
Combination With Fulvestrant in Women With HR+/HER2-
Advanced Breast Cancer Who Had Progressed While
Receiving Endocrine Therapy.J. Clin. Oncol. 35 , 2875– 2884
(2017). doi:10.1200/JCO.2017.73.7585; pmid: 28580882 - M. P. Goetzet al., MONARCH 3: Abemaciclib As Initial
Therapy for Advanced Breast Cancer.J. Clin. Oncol. 35 ,
3638 – 3646 (2017). doi:10.1200/JCO.2017.75.6155;
pmid: 28968163 - S. Johnstonet al., MONARCH 3 final PFS: A randomized
study of abemaciclib as initial therapy for advanced breast
cancer.NPJ Breast Cancer 5 , 5 (2019). doi:10.1038/
s41523-018-0097-z; pmid: 30675515- S. A. Imet al., Overall Survival with Ribociclib plus
Endocrine Therapy in Breast Cancer.N.Engl.J.Med. 381 ,
307 – 316 (2019). doi:10.1056/NEJMoa1903765;
pmid: 31166679 - D. J. Slamonet al., Overall Survival with Ribociclib plus
Fulvestrant in Advanced Breast Cancer.N. Engl. J. Med. 382 ,
514 – 524 (2020). doi:10.1056/NEJMoa1911149;
pmid: 31826360 - G. W. Sledge Jret al., The Effect of Abemaciclib Plus
Fulvestrant on Overall Survival in Hormone Receptor-Positive,
ERBB2-Negative Breast Cancer That Progressed on
Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
JAMA Oncol. 6 , 116–124 (2020). pmid: 31563959 - N. C. Turneret al., Overall Survival with Palbociclib and
Fulvestrant in Advanced Breast Cancer.N. Engl. J. Med. 379 ,
1926 – 1936 (2018). doi:10.1056/NEJMoa1810527;
pmid: 30345905 - M. N. Dickleret al., MONARCH 1, A Phase II Study of
Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent,
in Patients with Refractory HR+/HER2–Metastatic Breast
Cancer.Clin. Cancer Res. 23 , 5218–5224 (2017). doi:10.1158/
1078-0432.CCR-17-0754; pmid: 28533223 - S. R. D. Johnstonet al., Abemaciclib Combined With
Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-,
Node-Positive, High-Risk, Early Breast Cancer (monarchE).
J. Clin. Oncol. 38 , 3987–3998 (2020). doi:10.1200/
JCO.20.02514; pmid: 32954927 - E. L. Mayeret al., LBA12 - PALLAS: A randomized phase III
trial of adjuvant palbociclib with endocrine therapy versus
endocrine therapy alone for HR+/HER2- early breast
cancer.Ann. Oncol. 31 (suppl. 4), S1142–S1215 (2020).
doi:10.1016/j.annonc.2020.08.2240 - S. Pernas, S. M. Tolaney, E. P. Winer, S. Goel, CDK4/6
inhibition in breast cancer: Current practice and future
directions.Ther. Adv. Med. Oncol. 10 , 1758835918786451
(2018). doi:10.1177/1758835918786451; pmid: 30038670
139.www.clinicaltrials.gov/. - J. L. Deanet al., Therapeutic response to CDK4/6 inhibition
in breast cancer defined by ex vivo analyses of human
tumors.Cell Cycle 11 , 2756–2761 (2012). doi:10.4161/
cc.21195; pmid: 22767154 - M. T. Herrera-Abreuet al., Early Adaptation and
Acquired Resistance to CDK4/6 Inhibition in Estrogen
Receptor-Positive Breast Cancer.Cancer Res. 76 ,
2301 – 2313 (2016). doi:10.1158/0008-5472.CAN-15-0728;
pmid: 27020857 - R. Condorelliet al., Polyclonal RB1 mutations and acquired
resistance to CDK 4/6 inhibitors in patients with metastatic
breast cancer.Ann. Oncol. 29 , 640–645 (2018). doi:10.1093/
annonc/mdx784; pmid: 29236940 - B. O’Learyet al., The Genetic Landscape and Clonal
Evolution of Breast Cancer Resistance to Palbociclib plus
Fulvestrant in the PALOMA-3 Trial.Cancer Discov. 8 ,
1390 – 1403 (2018). doi:10.1158/2159-8290.CD-18-0264;
pmid: 30206110 - C. Costaet al., PTEN Loss Mediates Clinical Cross-Resistance
to CDK4/6 and PI3KaInhibitors in Breast Cancer.
Cancer Discov. 10 , 72–85 (2020). doi:10.1158/
2159-8290.CD-18-0830; pmid: 31594766 - S. A. Wanderet al., The Genomic Landscape of Intrinsic and
Acquired Resistance to Cyclin-Dependent Kinase 4/6
Inhibitors in Patients with Hormone Receptor-Positive
Metastatic Breast Cancer.Cancer Discov. 10 , 1174– 1193
(2020). doi:10.1158/2159-8290.CD-19-1390;
pmid: 32404308 - C. Yanget al., Acquired CDK6 amplification promotes breast
cancer resistance to CDK4/6 inhibitors and loss of ER
signaling and dependence.Oncogene 36 , 2255–2264 (2017).
doi:10.1038/onc.2016.379; pmid: 27748766 - L. Formisanoet al., Aberrant FGFR signaling mediates
resistance to CDK4/6 inhibitors in ER+ breast cancer.
Nat. Commun. 10 , 1373 (2019). doi:10.1038/
s41467-019-09068-2; pmid: 30914635 - M. Álvarez-Fernández, M. Malumbres, Mechanisms of
Sensitivity and Resistance to CDK4/6 Inhibition.Cancer Cell
37 , 514–529 (2020). doi:10.1016/j.ccell.2020.03.010;
pmid: 32289274 - L. Cenet al., p16-Cdk4-Rb axis controls sensitivity to a cyclin-
dependent kinase inhibitor PD0332991 in glioblastoma
xenograft cells.Neuro-oncol. 14 , 870–881 (2012).
doi:10.1093/neuonc/nos114; pmid: 22711607
150. M. E. Olanichet al., CDK4 Amplification Reduces Sensitivity
to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
Clin. Cancer Res. 21 , 4947–4959 (2015). doi:10.1158/
1078-0432.CCR-14-2955; pmid: 25810375
151. L. Cornell, S. A. Wander, T. Visal, N. Wagle, G. I. Shapiro,
MicroRNA-Mediated Suppression of the TGF-bPathway Confers
Transmissible and Reversible CDK4/6 Inhibitor Resistance.
Cell Rep. 26 , 2667–2680.e7 (2019). doi:10.1016/
j.celrep.2019.02.023; pmid: 30840889
152. R. de Leeuwet al., MAPK Reliance via Acquired CDK4/6 Inhibitor
Resistance in Cancer.Clin. Cancer Res. 24 , 4201–4214 (2018).
doi:10.1158/1078-0432.CCR-18-0410; pmid: 29739788
153. E. Haineset al., Palbociclib resistance confers dependence
on an FGFR-MAP kinase-mTOR-driven pathway inKRAS-mutant
non-small cell lung cancer.Oncotarget 9 , 31572– 31589
(2018). doi:10.18632/oncotarget.25803; pmid: 30167080
154. G. Romanoet al., A Preexisting RarePIK3CAE545K
Subpopulation Confers Clinical Resistance to MEK plus
CDK4/6 Inhibition inNRASMelanoma and Is Dependent on
S6K1 Signaling.Cancer Discov. 8 , 556–567 (2018).
doi:10.1158/2159-8290.CD-17-0745; pmid: 29496665
155. D. B. Bowe, N. J. Kenney, Y. Adereth, I. G. Maroulakou,
Suppression of Neu-induced mammary tumor growth in
cyclin D1 deficient mice is compensated for by cyclin E.
Oncogene 21 , 291–298 (2002). doi:10.1038/sj.onc.1205025;
pmid: 11803472
156. Y. Genget al., Rescue of cyclin D1 deficiency by knockin
cyclin E.Cell 97 , 767–777 (1999). doi:10.1016/S0092-8674
(00)80788-6; pmid: 10380928
157. L. Wanget al., Pharmacologic inhibition of CDK4/6:
Mechanistic evidence for selective activity or acquired
resistance in acute myeloid leukemia.Blood 110 , 2075– 2083
(2007). doi:10.1182/blood-2007-02-071266; pmid: 17537993
158. A. E. Vilgelmet al., MDM2 antagonists overcome intrinsic
resistance to CDK4/6 inhibition by inducing p21.Sci. Transl. Med.
11 , eaav7171 (2019). doi:10.1126/scitranslmed.aav7171;
pmid: 31413145
159. E. S. Knudsenet al., Cell cycle plasticity driven by MTOR
signaling: Integral resistance to CDK4/6 inhibition in
patient-derived models of pancreatic cancer.Oncogene 38 ,
3355 – 3370 (2019). doi:10.1038/s41388-018-0650-0;
pmid: 30696953
160. V. M. Jansenet al., Kinome-Wide RNA Interference Screen
Reveals a Role for PDK1 in Acquired Resistance to CDK4/6
Inhibition in ER-Positive Breast Cancer.Cancer Res. 77 ,
2488 – 2499 (2017). doi:10.1158/0008-5472.CAN-16-2653;
pmid: 28249908
161. A. Yoshidaet al., SLC36A1-mTORC1 signaling drives acquired
resistance to CDK4/6 inhibitors.Sci. Adv. 5 , eaax6352 (2019).
doi:10.1126/sciadv.aax6352; pmid: 31555743
162. J. I. Griffithset al., Convergent evolution of resistance
pathways during early stage breast cancer treatment with
combination cell cycle (CDK) and endocrine inhibitors.
Cancer Res. 81 (suppl. 4), SP012 (2021). doi:10.1101/
2021.01.19.427299
163. R. L. Hoffman,“The discovery of PF-07104091: A CDK2 selective
inhibitor for the treatment of cyclinE amplified cancers.”
Paper presented at the AACR Annual Meeting 2021, Session
DDT02—New Drugs on the Horizon: Part 3 (2021).
164. Y. J. Choiet al., Development of a selective CDK2-E inhibitor
in CCNE driven cancers.Cancer Res. 81 (suppl. 13), 1279
(2021). doi:10.1158/1538-7445.AM2021-1279
165. K. Freeman-Cooket al., Expanding control of the tumor
cell cycle with a CDK2/4/6 inhibitor.Cancer Cell 39 , 1404–1421.
e11 (2021). doi:10.1016/j.ccell.2021.08.009; pmid: 34520734
166. P. Hydbring, M. Malumbres, P. Sicinski, Non-canonical
functions of cell cycle cyclins and cyclin-dependent kinases.
Nat. Rev. Mol. Cell Biol. 17 , 280–292 (2016). doi:10.1038/
nrm.2016.27; pmid: 27033256
ACKNOWLEDGMENTS
We thank L. Bury for help with the illustrations.Funding:
Supported by a Claudia Adams Barr Program for Innovative
Basic Cancer Research Award (A.F.), NIH grant R50CA243769
(Y.G.), and NIH grants R01CA202634, CA236226, P50CA168504,
and P01CA250959 (P.S.).Competing interests:P.S. has been
a consultant at Novartis, Genovis, Guidepoint, The Planning
Shop, ORIC Pharmaceuticals, Cedilla Therapeutics, Syros
Pharmaceuticals, and Exo Therapeutics; his laboratory receives
funding from Novartis.10.1126/science.abc1495Fasslet al.,Science 375 , eabc1495 (2022) 14 January 2022 19 of 19
RESEARCH | REVIEW